

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

### New triterpenes from *Salacia hainanensis* Chun et How with $\alpha$ -glucosidase inhibitory activity

Hui-Yuan Gao<sup>ab</sup>; Zheng-Hong Guo<sup>ab</sup>; Peng Cheng<sup>ab</sup>; Xiao-Min Xu<sup>ab</sup>; Li-Jun Wu<sup>ab</sup>

<sup>a</sup> School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China <sup>b</sup> Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China

Online publication date: 28 September 2010

**To cite this Article** Gao, Hui-Yuan , Guo, Zheng-Hong , Cheng, Peng , Xu, Xiao-Min and Wu, Li-Jun(2010) 'New triterpenes from *Salacia hainanensis* Chun et How with  $\alpha$ -glucosidase inhibitory activity', *Journal of Asian Natural Products Research*, 12: 10, 834 – 842

**To link to this Article:** DOI: 10.1080/10286020.2010.503653

URL: <http://dx.doi.org/10.1080/10286020.2010.503653>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## ORIGINAL ARTICLE

### New triterpenes from *Salacia hainanensis* Chun et How with $\alpha$ -glucosidase inhibitory activity

Hui-Yuan Gao\*, Zheng-Hong Guo, Peng Cheng, Xiao-Min Xu and Li-Jun Wu

School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China; Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China

(Received 26 April 2010; final version received 20 June 2010)

Fractionation of the methanol extract from the roots of *Salacia hainanensis* Chun et How showing the potent inhibitory activity on  $\alpha$ -glucosidase afforded two new lupane derivatives, 3 $\alpha$ ,28-dihydroxy-lup-20(29)-en-2-one (**1**) and 3 $\alpha$ -hydroxy-lup-20(29)-en-2-one (**2**), a new friedelane derivative, D:A-friedo-oleanane-7 $\alpha$ ,30-dihydroxy-3-one (**3**), and a novel natural product, 2,3-*seco*-lup-20(29)-en-2,3-dioic acid (**4**), along with four known compounds (**5**–**8**). Their structures were established on the basis of spectral analysis, especially on the data afforded by 2D NMR and high-resolution mass spectra experiments. All of them showed a much stronger inhibiting activity on  $\alpha$ -glucosidase than the positive control (acarbose, IC<sub>50</sub> = 5.83  $\mu$ M). Constituents with  $\alpha$ -glucosidase inhibitory activity from this plant are reported for the first time.

**Keywords:** Hippocrateaceae; *Salacia hainanensis* Chun et How; lupane; friedelane;  $\alpha$ -glucosidase; antidiabetes

#### 1. Introduction

Much attention has been given to the prevention and the treatment of diabetes, which is a complex metabolic disorder caused by insulin insufficiency and/or insulin dysfunction and characterized by aberrant blood glucose and insulin levels, and has an increasingly adverse impact on morbidity, mortality, and overall health care costs worldwide [1]. Complications caused by diabetes are considered as the main reason for health damage, even death. Recently, the inhibitors of glycosidases including intestinal  $\alpha$ -glucosidase inhibitors have been postulated to be powerful therapeutic agents in carbohydrate metabolic disorders, especially in diabetes mellitus [2,3].

*Salacia hainanensis* Chun et How, family Hippocrateaceae, is a special species used as a traditional medicine in Hainan Province of China. Its root and stem have been widely used for the treatment of rheumatoid joint pain, strain of lumbar muscles, weakness, and asthenia [4]. The aqueous extract from the roots of *S. hainanensis* had been reported to show hypoglycemic activity in mice and can significantly reduce the blood glucose levels of alloxan and glucose-loaded mice [5]. However, the pharmacologically active components were unclear. In the course of our studies on antidiabetogenic compounds from natural medicines, the inhibitory activity on  $\alpha$ -glucosidase of the methanol (MeOH) extract from its roots

\*Corresponding author. Email: gaohuiyuan1997@yahoo.com.cn

was evaluated, which showed a very potent inhibitory effect. By means of various chromatographic methods, the extract gave eight triterpene derivatives. This paper describes the isolation and the structural elucidation of the constituents from *S. hainanensis*, together with their  $\alpha$ -glucosidase inhibitory activities.

## 2. Results and discussion

During the process of the chemical study on this plant, two new lupane derivatives, 3 $\alpha$ ,28-dihydroxy-lup-20(29)-en-2-one (**1**) and 3 $\alpha$ -hydroxy-lup-20(29)-en-2-one (**2**), a new friedelane derivative, D:A-friedo-oleanane-7 $\alpha$ ,30-dihydroxy-3-one (**3**), and a novel natural product, 2,3-*seco*-lup-20(29)-en-2,3-dioic acid (**4**), as well as four known compounds, lup-20(29)-en-3,21-dione (**5**) [6], amyrin (**6**) [7], 30-hydroxy-friedelan-3-one (**7**) [8], and 24*S*,25-dihydroxy-triucall-7-en-3-one (**8**) [9], were isolated (Figure 1).

Compound **1** was obtained as a white amorphous powder (CH<sub>2</sub>Cl<sub>2</sub>). Its molecular formula was assigned to be C<sub>30</sub>H<sub>48</sub>O<sub>3</sub> by a positive ion peak at  $m/z$  479.3495 [M + Na]<sup>+</sup> in the high-resolution electrospray ionization mass spectra (HR-ESI-MS). The absorption bands at 3480, 1713, 1640, and 773 cm<sup>-1</sup> in the IR

spectrum indicated the presence of hydroxyl, carbonyl, and double bond functions in the structure. Its <sup>1</sup>H NMR spectrum showed signals for six methyl [ $\delta_H$  0.70, 0.81, 1.19, 1.70 (each 3H, all s), 1.04 (6H, s)], two olefinic protons [ $\delta_H$  4.61 (1H, br s), 4.71 (1H, br s)], an oxygen-substituted methine at  $\delta_H$  3.89 (1H, s), one oxomethylene [ $\delta_H$  3.36, 3.82 (each 1H, d,  $J = 12.0$  Hz)], and other alkyl groups (Table 1). There were 30 carbon signals in the <sup>13</sup>C NMR spectrum (Table 1) including a ketone group ( $\delta_C$  211.4), one oxygen-substituted methine ( $\delta_C$  82.5), two olefinic carbons ( $\delta_C$  109.9 and 150.2), one oxomethylene ( $\delta_C$  60.5), and other alkyl groups consisting of six methyl, nine methylene, five methine, and five quaternary carbons. These data provided the evidence that **1** was a 3,28-dihydroxy-lup-20(29)-ene derivative, especially from the chemical shifts of its olefinic carbon signals [10]. The ketone group was assigned to the C-2 position by the long-range correlations between H-3 ( $\delta_H$  3.89) and carbonyl [ $\delta_C$  211.4 (C-2)], which also showed correlations with H-1 [ $\delta_H$  2.56 (d, 12.0), 2.04 (d, 12.0)] in the HMBC spectrum. The NOESY cross-peaks of H-3/CH<sub>3</sub>-25/CH<sub>3</sub>-24, CH<sub>3</sub>-25/CH<sub>3</sub>-26, and H-19/H-28 were observed, which




Figure 1. Structures of compounds **1**–**8**.

Table 1.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectral data of compounds 1–4 ( $\text{CDCl}_3$ ,  $J$  in Hz).

Position	1		2		3		4	
	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$
1	2.56 (d, $J = 12.0$ ) 2.04 (d, $J = 12.0$ )	53.5	2.03 (d, $J = 12.3$ ) 2.53 (d, $J = 12.3$ )	53.4	2.02 (d, $J = 3.9$ )	21.9	2.63 (d, $J = 19.8$ ) 2.46 (d, $J = 19.8$ )	40.9
2	3.89 (s)	211.4	3.88 (s)	211.5	2.34–2.41 <sup>a</sup>	41.2		178.5
3		82.5		82.9		212.4		187.5
4		45.6		45.6	2.32 (s)	58.2		45.6
5	1.44 <sup>a</sup>	54.6	1.43 <sup>a</sup>	54.6		42.6	1.36 <sup>a</sup>	48.2
6	1.67 <sup>a</sup>	18.5	1.63 (d, $J = 4.8$ )	18.5	2.02 (d, $J = 3.9$ )	52.2	1.34 <sup>a</sup>	21.3
	1.52 <sup>a</sup>		1.52 (d, $J = 4.8$ )		1.41 <sup>a</sup>			
7	1.07 <sup>a</sup>	34.0	1.06 (m)	33.8	4.12 (t, $J = 10.5$ )	68.6	1.40 (d, $J = 4.2$ )	33.7
	1.88 (m)		1.86 (m)				1.51 <sup>a</sup>	
8		41.3		41.2	1.50 <sup>a</sup>	58.6		41.8
9	1.61 <sup>a</sup>	50.4	1.60 <sup>a</sup>	50.4		39.0	2.53 <sup>a</sup>	41.7
10		43.9		44.0	1.55 <sup>a</sup>	58.9		40.7
11	1.28 (d, $J = 12.0$ ) 1.33 (d, $J = 12.0$ )	21.0	1.28 (d, $J = 11.7$ ) 1.33 (d, $J = 11.7$ )	21.1	1.41 <sup>a</sup>	35.9	1.65 <sup>a</sup>	19.2
	1.08 <sup>a</sup>		1.09 <sup>a</sup>		1.33 <sup>a</sup>		1.50 <sup>a</sup>	
12	1.68 <sup>a</sup>	25.1	1.66 <sup>a</sup>	24.8	1.27 <sup>a</sup>	29.6	1.67 (dd, $J = 12.6, 4.2$ )	24.9
	1.68 <sup>a</sup>		1.67 <sup>a</sup>				1.70 (dd, $J = 12.6, 4.0$ )	
13		37.2		37.9		40.3	1.60 (dd, $J = 3.6, 11.4$ )	37.9
14		42.8		42.9		40.0		43.2
15	1.10 <sup>a</sup>	27.1	1.50 <sup>a</sup>	29.4	1.52 <sup>a</sup>	29.5	1.67 <sup>a</sup>	27.5
	1.73 <sup>a</sup>		1.71 <sup>a</sup>				1.04 (d, $J = 2.4$ )	
16	2.04 (2H) <sup>a</sup>	29.3	2.03 (2H, m)	35.4	1.00 (m)	38.3	1.49 <sup>a</sup>	35.5
					1.53 <sup>a</sup>		1.39 (d, $J = 6.0$ )	
17		47.8		42.9		30.4		43.2
18	1.62 <sup>a</sup>	48.7	1.63 <sup>a</sup>	48.2	1.53 <sup>a</sup>	42.3	2.52 (d, $J = 11.4$ )	48.4
19	2.40 (td, $J = 10.9, 6.0$ )	47.8	2.40 (td, $J = 10.7, 6.1$ )	47.9	1.71 <sup>a</sup>	35.3	2.38 (td, $J = 11.4, 6.0$ )	48.0
					2.02 (m)			
20		150.2		150.7		33.5		150.9
21	1.42 (d, $J = 12.0$ ) 1.97 (d, $J = 10.8$ )	29.7	1.43 (m) 2.03 (m)	29.8	1.19 (m) 1.41 (m)	27.9	1.92 (m) 1.33 <sup>a</sup>	29.8

Table 1 – continued

Position	1		2		3		4	
	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$
22	1.50 <sup>a</sup>	33.8	1.50 (m)	29.9	1.62 <sup>a</sup>	36.1	1.38 (d, $J = 12.0$ )	39.9
23	1.88		1.88 (m)				1.39 (d, $J = 12.0$ )	
24	1.19 (3H, s)	29.1	1.17 (3H, s)	29.2	0.92 (d, $J = 6.5$ )	6.9	1.17 (3H, s)	29.8
25	0.70 (3H, s)	16.4	0.68 (3H, s)	16.4	0.82 (3H, s)	15.9	1.27 (3H, s)	21.3
26	0.81 (3H, s)	17.0	0.79 (3H, s)	17.0	0.94 (3H, s)	18.9	0.93 (3H, s)	20.8
27	1.04 (3H, s)	14.8	1.03 (3H, s)	15.6	1.10 (3H, s)	19.1	1.03 (3H, s)	15.9
28	1.04 (3H, s)	15.6	0.99 (3H, s)	14.5	1.24 (3H, s)	20.8	0.94 (3H, s)	14.6
	3.36 (d, $J = 12.0$ )	60.5	0.79 (3H, s)	18.0	1.20 (3H, s)	31.8	0.78 (3H, s)	18.0
	3.82 (d, $J = 12.0$ )							
29	4.61 (br s)	109.9	4.57 (1H, s)	109.5	1.01 (3H, s)	29.1	4.57 (br s)	109.4
	4.71 (br s)		4.69 (1H, s)				4.09 (br s)	
30	1.70 (3H, s)	19.1	1.68 (3H, s)	19.3	3.40 (d, $J = 10.2$ )	71.3	1.69 (3H, s)	19.2
					3.46 (d, $J = 10.2$ )			

Note: <sup>a</sup> Overlapped signals were reported without designating multiplicity.




Figure 2. Key HMBC and NOESY correlations of compound **1**.

suggested that the hydroxyl group linked with C-3 was in the  $\alpha$ -oriented form (Figure 2). Based on the above analysis, compound **1** was elucidated as 3 $\alpha$ ,28-dihydroxy-lup-20(29)-en-2-one (Figure 1).

Compound **2** was isolated as a white solid powder ( $\text{CH}_2\text{Cl}_2$ ) with a molecular formula of  $\text{C}_{30}\text{H}_{48}\text{O}_2$  determined by a positive  $[\text{M} + \text{Na}]^+$  ion peak at  $m/z$  463.3545 in HR-ESI-MS. Its IR spectrum displayed absorption bands arising from the hydroxyl ( $3500\text{ cm}^{-1}$ ), carbonyl ( $1707\text{ cm}^{-1}$ ), and double bond ( $1642\text{ cm}^{-1}$ ) groups. The data afforded by the  $^1\text{H}$  and  $^{13}\text{C}$  NMR (Table 1) spectra suggested that compound **2** was a derivative of **1** with the difference being that  $\text{C}_{28}\text{-OH}$  was reduced to be a methyl group. In the HMBC spectrum, the long-range correlations between  $\text{CH}_3\text{-28}$  [ $\delta_{\text{H}}$  0.79 (3H, s)] and C-17, C-18, and C-22 ( $\delta_{\text{C}}$  42.9, 48.2, and 29.9, respectively) were also found; therein, compound **2** was determined to be 3 $\alpha$ -hydroxy-lup-20(29)-en-2-one (Figure 1).

Compound **3** was obtained as white needles ( $\text{CH}_2\text{Cl}_2$ ). Its molecular formula was assigned to be  $\text{C}_{30}\text{H}_{50}\text{O}_3$  by a positive ion peak at  $m/z$  481.3649 in the HR-ESI-MS. The IR spectrum showed absorption bands at  $3501$  and  $1707\text{ cm}^{-1}$  ascribable to hydroxyl and carbonyl functions. Its  $^1\text{H}$  (300 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR

(150 MHz,  $\text{CDCl}_3$ ) spectral data (Table 1) suggested that compound **3** was a hydroxylated derivative of D:A-friedo-oleanane-30-hydroxy-3-one (**3**) [8], which was also obtained in this work as compound **7**. In the HMBC experiment, the presence of the long-range correlations between H-2 [ $\delta_{\text{H}}$  2.34–2.41 (2H, m)] and C-3 ( $\delta_{\text{C}}$  212.4); H-6 [ $\delta_{\text{H}}$  2.02 (1H, d,  $J = 3.9$  Hz) and 1.41 (1H, overlap)] and C-7 ( $\delta_{\text{C}}$  68.6) suggested that the hydroxyl group should be assigned to the C-7 position, and the key correlations are exhibited in Figure 3. Moreover, the NOESY correlations of H-7/ $\text{CH}_3\text{-24}$ , 25, 26,  $\text{CH}_3\text{-28}$ /H-30,  $\text{CH}_3\text{-29}$ / $\text{CH}_3\text{-27}$  suggested that the orientation of  $\text{C}_7\text{-OH}$  was in the  $\alpha$  form. Thus, compound **3** was elucidated to be D:A-friedo-oleanane-7 $\alpha$ ,30-dihydroxy-3-one.

Compound **4** had the molecular formula of  $\text{C}_{30}\text{H}_{48}\text{O}_4$  determined by its pseudomolecular ion  $[\text{M} + \text{Na}]^+$  at  $m/z$  495.3445 in its HR-ESI-MS spectrum. Its  $^1\text{H}$  NMR spectrum (Table 1) revealed the presence of seven methyls [ $\delta_{\text{H}}$  0.78, 0.93, 0.94, 1.03, 1.17, 1.27, and 1.69 (each 3H, s)], two olefinic protons [ $\delta_{\text{H}}$  4.57 (1H, br s) and 4.09 (1H, br s)], and other alkyl groups. Thirty carbon signals were shown in its  $^{13}\text{C}$  NMR spectrum (Table 1), and two olefinic carbons at  $\delta_{\text{C}}$  109.4 and 150.9 were characteristic of the lup-20(29)-en




Figure 3. Key HMBC and NOESY correlations of compound 3.

skeleton. In addition, signals at  $\delta_C$  178.5 and 187.5 indicated the existence of two carboxylic groups in compound 4. Its HMBC spectrum gave the key correlations of H-1 ( $\delta_H$  2.46, 2.63) and C-2 ( $\delta_C$  178.5); CH<sub>3</sub>-23 [ $\delta_H$  1.17 (3H, s)] and C-3, 5 ( $\delta_C$  187.5, 48.2); CH<sub>3</sub>-24 ( $\delta_H$  1.27) and C-4 ( $\delta_C$  45.6), C-5; and CH<sub>3</sub>-25 [ $\delta_H$  0.93 (3H, s)] and C-1 ( $\delta_C$  40.9), C-10 ( $\delta_C$  40.7), which suggested that compound 4 had a 2,3-*seco*-A ring in the structure and two carboxylic signals were assigned to the C-2 and C-3 positions, respectively. Thus, compound 4 was determined to be 2,3-*seco*-lup-20(29)-en-2,3-dioic acid (Figure 4), as a novel natural product, which was found as a medium product during a chemical reaction




Figure 4. Key HMBC correlations of compound 4.

[11] firstly and its proton and carbon signals were assigned completely for the first time here.

An assay was carried out for the inhibition of  $\alpha$ -glucosidase using the main extract (MeOH) and subsequent partitions with ethyl acetate (EtOAc), *n*-butanol (*n*-BuOH), and the aqueous extract (Table 2). It was found that the activity occurred in all fractions. The IC<sub>50</sub> values of each fraction indicated their potent inhibitory effects. In addition, compounds 1–8 were tested for their inhibitory activities (Table 3). All of them showed a much stronger inhibitory activity than the positive control. Among these, the most potent inhibitor was 4, with an IC<sub>50</sub> value of 0.01  $\mu$ M. Its structural features including the 2,3-*seco* of ring A and the existence of two carboxylic groups may be responsible for its significant inhibitory property. This result would be helpful to clarify the importance of exploiting the useful resource for *S. hainanensis*.

### 3. Experimental

#### 3.1 General experimental procedures

Optical rotations were obtained on a Perkin-Elmer 341 polarimeter at room temperature. IR spectra were measured on a Bruker IFS-55 Fourier transform infrared spectrometer.

Table 2. Inhibition activities of the extracts of *S. hainanensis* on  $\alpha$ -glucosidase (IC<sub>50</sub>).

Assay	IC <sub>50</sub> <sup>a</sup> (mg/ml)				
	Main extract	Fractions			Positive control
	MeOH	EtOAc	<i>n</i> -BuOH	H <sub>2</sub> O	Acarbose
$\alpha$ -Glucosidase	0.26	0.27	0.03	0.05	3.76

Note: <sup>a</sup>IC<sub>50</sub> values were calculated from dose-dependent inhibition curves.

NMR spectral data were recorded on Bruker AV-600 and ARX-300 spectrometers and chemical shifts were shown as  $\delta$ -values (ppm) with tetramethyl silane as an internal standard, including NOE, HMQC, and HMBC. HR-ESI-MS were recorded on a Bruker micro-TOF-Q mass spectrometer. HPLC separation was carried out on a reversed-phase Mightysil packed column using the gradient CH<sub>3</sub>CN–H<sub>2</sub>O and MeOH–H<sub>2</sub>O solvent systems with detection at 210 nm. Silica gel for column chromatography (CC, 200–300 mesh) and TLC plates (GF<sub>254</sub>) were purchased from Qingdao Marine Chemical Ltd (Qingdao, China), and spots were visualized by spraying the plates with 10% H<sub>2</sub>SO<sub>4</sub> solution, followed by heating. All chemical agents used were of biochemical reagent grade. A molecular device spectrophotometer was used for the measurement of enzyme inhibition.

### 3.2 Plant material

The roots of *S. hainanensis* Chun et How were collected from Baoting County in Hainan Province of China in September

Table 3. Inhibitory activities of compounds 1–8 on  $\alpha$ -glucosidase (IC<sub>50</sub>).

Compound	IC <sub>50</sub> ( $\mu$ M)
1	0.26
2	0.09
3	0.87
4	0.01
5	0.07
6	0.19
7	0.08
8	0.30
Acarbose	5.83

2007 and taxonomically identified by Prof. Qi-shi Sun (School of Traditional Chinese Medicine, Shenyang Pharmaceutical University). The voucher specimen (No. ZB-2007-26) has been deposited at the same department.

### 3.3 Extraction and isolation

Air-dried roots of *S. hainanensis* (5.5 kg) were extracted with MeOH under reflux for two times. The solution was evaporated under vacuum to obtain a brown viscous residue (491 g), which was suspended in water (1200 ml) and extracted with EtOAc and BuOH successively, to yield the EtOAc (SMA, 78 g), *n*-BuOH (SMB, 100 g), and aqueous (SMW, 232.8 g) soluble fractions.

SMA (75 g) was fractionated using silica gel CC with a gradient of CHCl<sub>3</sub>–MeOH (100:0, 100:2, 100:3, 100:5, 100:10, 100:20, and 0:100) to give seven fractions (Fr. 1–7). Fr. 4 (2.6 g) was subjected to silica gel CC (petroleum ether (PE)–acetone, 30:1) again to afford four subfractions (Fr. 4.1–4.4). Then, subfraction Fr. 4.1 (0.4 g) was purified with reversed-phase HPLC [MeOH–H<sub>2</sub>O (86:14)] to furnish compound **7** (15 mg, *t*<sub>R</sub> 50.3 min). Fr. 4.2 (0.7 g) was also applied to HPLC [MeOH–H<sub>2</sub>O (85:15)] to afford compounds **1** (4 mg, *t*<sub>R</sub> 27.0 min) and **3** (5 mg, *t*<sub>R</sub> 38.5 min). Compound **8** (5 mg) was crystallized from Fr. 7 (1.4 g) subjected to silica gel CC and eluted with CH<sub>2</sub>Cl<sub>2</sub>–MeOH (30:1). From Fr. 5 (2 g), compounds **2** (6 mg, *t*<sub>R</sub> 60.5) and **5** (3 mg,



$t_R$  28.0 min) were obtained after purification with HPLC [MeOH–H<sub>2</sub>O (95:5)].

BuOH extract (100 g) was fractionated using silica gel CC with a gradient of CH<sub>2</sub>Cl<sub>2</sub>–MeOH (100:2, 100:4, 100:10, 100:20, 100:30, and 0:100) to give six fractions (Fr. 1–6). Fr. 1 (3 g) was further separated on silica gel CC with solvents PE–acetone (40:1) to give compound **6** (6 mg). In addition, the rechromatography of Fr. 2 (1.5 g) on a silica gel column with PE–acetone (40:1) generated three subfractions (Fr. 2.1–2.3), and then, subfraction 2.3 (0.2 mg) was purified by HPLC [MeOH–H<sub>2</sub>O (65:35)] to afford compound **4** (16 mg,  $t_R$  71.0 min).

### 3.3.1 3 $\alpha$ ,28-Dihydroxy-lup-20(29)-en-2-one (**1**)

A white powder (CH<sub>2</sub>Cl<sub>2</sub>),  $[\alpha]_D^{21} + 42.9$  ( $c = 0.05$ , CH<sub>2</sub>Cl<sub>2</sub>); IR (KBr)  $\nu_{\max}$ : 3480 (–OH), 1713 (C=O), 1640 (C=C), 1454, 1219, 1025, 773 cm<sup>–1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) spectral data, see Table 1. HR-ESI-MS:  $m/z$  479.3495 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>Na, 479.3496).

### 3.3.2 3 $\alpha$ -Hydroxy-lup-20(29)-en-2-one (**2**)

A white powder (CH<sub>2</sub>Cl<sub>2</sub>);  $[\alpha]_D^{23} + 49.7$  ( $c = 0.08$ , CH<sub>2</sub>Cl<sub>2</sub>); IR (KBr)  $\nu_{\max}$ : 3500 (–OH), 3078 (=CH), 2936, 2872, 1708 (C=O), 1642 (C=C), 1454, 1383, 1056, 881 cm<sup>–1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) spectral data, see Table 1; HR-ESI-MS:  $m/z$  463.3545 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>48</sub>O<sub>2</sub>Na, 463.3547)].

### 3.3.3 D:A-friedo-oleanane-7 $\alpha$ ,30-dihydroxy-3-one (**3**)

White needles (CH<sub>2</sub>Cl<sub>2</sub>);  $[\alpha]_D^{23} - 17.5$  (CH<sub>2</sub>Cl<sub>2</sub>,  $c = 0.85$ ); IR (KBr)  $\nu_{\max}$ : 3501, 1708 cm<sup>–1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz) spectral data, see Table 1; HR-ESI-MS:

$m/z$  481.3649 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>50</sub>O<sub>3</sub>Na, 481.3652).

### 3.3.4 2,3-*seco*-Lup-20(29)-en-2,3-dioic acid (**4**)

A white powder (CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz) spectral data, see Table 1; HR-ESI-MS:  $m/z$  495.3445 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>48</sub>O<sub>4</sub>Na, 495.3445).

## 3.4 Glycosidase inhibition assay

The  $\alpha$ -glucosidase (Sigma Chemical Company, Shanghai, China) inhibition assay was performed according to the reported methods with slight modification [12]. Thirty microliters of a 0.02 U/ $\mu$ l enzyme in 0.2 M phosphate buffer (pH 6.8) and in the presence or absence of various concentrations of the test compounds in 0.2 M phosphate buffer (pH 6.8) were incubated in 96-well plates at 37°C for 10 min. Then, 140  $\mu$ l of 0.02 M *p*-nitrophenyl- $\alpha$ -D-glucosidase (PNPG; Sigma Chemical Company) in 0.2 M phosphate buffer (pH 6.8) was added, and the plate was incubated at 37°C for another 30 min. The reaction was quenched by the addition of 0.2 M Na<sub>2</sub>CO<sub>3</sub> solution (2 ml). Acarbose (Germany Bayer Chemical Ltd, Shanghai, China) was tested as a positive control. The increment in absorption at 450 nm due to the hydrolysis of PNPG by glycosidase was monitored on a microplate spectrophotometer (Bio-Rad, Hercules, CA, USA). The concentration of samples required to inhibit 50% of their activities under the assay conditions was defined as the IC<sub>50</sub> value.

## Acknowledgements

We thank Mrs Wen Li, Mr Yi Sha and Mr Weiming Cheng of the Analytical Centers of the Shenyang Pharmaceutical University for

recording NMR spectra and HR-ESI-MS. This work was supported by the National Natural Science Foundation Project of China (No. 30772717).

## References

- [1] S.A. Ross, E.A. Gulve, and M. Wang, *Chem. Rev.* **104**, 1255 (2004).
- [2] W. Dong, T. Jespersen, M. Bols, T. Skrydstrup, and M.R. Sierks, *Biochemistry* **35**, 2788 (1996).
- [3] M. Brownlee, *Nature* **414**, 813 (2001).
- [4] State Chinese Medicine Administration Bureau, *Chinese Materia Medica* (Shanghai Science Press, Shanghai, 1999).
- [5] G.J. Yuan, Y.W. Tian, and Z.Q. Wang, *Tradit. Chin. Drug Res. Clin. Pharmacol.* **16**, 253 (2005).
- [6] A. Hisham, G.J. Kumar, Y. Fujimoto, and N. Hara, *Phytochemistry* **40**, 1227 (1995).
- [7] J. Bhattacharyya and C.B. Barros, *Phytochemistry* **25**, 274 (1986).
- [8] N. Hiroshi, S. Hideyo, H. Teruhisa, K. Ryoji, R.Y. Wu, and K.H. Lee, *Phytochemistry* **25**, 479 (1986).
- [9] A.M. Dulcie, K. Maria, A.M. Hamdani, and A.H.T. David, *Phytochemistry* **49**, 2457 (1998).
- [10] O. Ayumi, I. Yoji, N. Meiko, A. Shinichi, K. Kanki, and T. Junko, *J. Nat. Prod.* **67**, 469 (2004).
- [11] A.K. Ganguly, T.R. Govindachari, and P.A. Mohamed, *Tetrahedron* **22**, 3597 (1966).
- [12] T. Matsui, T. Ueda, T. Oki, K. Sugita, N. Terahara, and K. Matsumoto, *J. Agric. Food Chem.* **49**, 1948 (2001).